Knollwood Investment Advisory LLC Has $10.60 Million Stock Position in Eli Lilly and Company $LLY

Knollwood Investment Advisory LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY) by 10.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,599 shares of the company’s stock after purchasing an additional 1,300 shares during the period. Eli Lilly and Company accounts for about 1.0% of Knollwood Investment Advisory LLC’s investment portfolio, making the stock its 16th biggest holding. Knollwood Investment Advisory LLC’s holdings in Eli Lilly and Company were worth $10,601,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Brighton Jones LLC grew its holdings in Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after purchasing an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC boosted its holdings in shares of Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after buying an additional 40 shares during the period. Covestor Ltd boosted its holdings in shares of Eli Lilly and Company by 24.9% during the 1st quarter. Covestor Ltd now owns 426 shares of the company’s stock worth $352,000 after buying an additional 85 shares during the period. Kaufman Rossin Wealth LLC acquired a new position in Eli Lilly and Company in the 1st quarter valued at $242,000. Finally, Exencial Wealth Advisors LLC raised its holdings in Eli Lilly and Company by 6.0% in the 1st quarter. Exencial Wealth Advisors LLC now owns 6,916 shares of the company’s stock worth $5,712,000 after acquiring an additional 390 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

LLY has been the subject of a number of recent analyst reports. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Scotiabank assumed coverage on Eli Lilly and Company in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $1,165.00 price target on the stock. National Bankshares set a $1,286.00 price objective on Eli Lilly and Company in a research report on Monday. Guggenheim reaffirmed a “buy” rating and set a $1,163.00 target price on shares of Eli Lilly and Company in a research report on Wednesday. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Eli Lilly and Company in a report on Monday. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $1,087.32.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $1,011.74 on Friday. The business has a fifty day simple moving average of $913.15 and a 200 day simple moving average of $807.53. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. The firm has a market capitalization of $956.48 billion, a price-to-earnings ratio of 49.50, a PEG ratio of 1.15 and a beta of 0.37. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,111.99.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The firm had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter in the previous year, the company earned $1.18 earnings per share. The business’s revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.